Nanotechnology-Based Cancer Treatment Can Reduce Side Effects

ByConnor Hodde

Conventional cancer treatments are accompanied by a host of side effects such as nausea and vomiting. The intensity of the side effects is many a time so acute that it poses a deterrent to further treatment. The reason behind the side effects is that existing cancer treatment methods do not address just the cancerous cells, but also affect the healthy cells in the proximity. By virtue of their extremely small size, drugs made of nanoparticles, can travel not only right inside the site of tumor through the tiny blood vessel passages, but also to individual diseased cells and carry out the healing process.

Read the article at http://cen.acs.org/articles/90/i23/Tiny-Tech-Treat-Cancer.html

Similar Posts

Surgeons perform world’s first operation inside the eye using a robot

ByConnor Hodde

Robert MacLaren, Professor of Ophthalmology. assisted by Dr Thomas Edwards, Nuffield Medical Fellow, used the remotely controlled robot to lift a membrane 100th of a millimetre thick from the retina at the back of the right eye of the Revd Dr William Beaver, 70, an Associate Priest at St Mary the Virgin, Iffley, Oxford. He…

Flexible Adult Stem Cells, Right There in Your Eye

ByConnor Hodde

Researchers reporting in the January issue of Cell Stem Cell, a Cell Press publication, have identified adult stem cells of the central nervous system in a single layer of cells at the back of the eye. That cell layer, known as the retinal pigment epithelium (RPE), underlies and supports photoreceptors in the light-sensitive retina. Without…

Calvert Labs and eyecro Announce Strategic Partnership in Ocular Research

ByConnor Hodde

Scott Township, PA – June 10, 2013 – Calvert Labs and eyecro, two leading providers in early-stage ocular drug research and development, announced today that they have entered into a strategic partnership to expedite preclinical drug development activities.  “This partnership will facilitate a seamless transition from the discovery and non-GLP stage of drug development to…

Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model

ByConnor Hodde

Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for…

Retinal Ischemia Tied to Variant of Acute Macular Neuroretinopathy

ByConnor Hodde

Paracentral acute middle maculopathy is a newly identified variant of acute macular neuroretinopathy that appears to result from retinal capillary ischemia, according to a retrospective observational case series. “This has been traditionally a very rare disease but now with advanced retinal imaging systems such as spectral domain optical coherence tomography (SD-OCT) and infrared reflectance imaging…